John B Easton
Overview
Explore the profile of John B Easton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cam H, Easton J, High A, Houghton P
Mol Cell
. 2010 Nov;
40(4):509-20.
PMID: 21095582
The mTOR complex-1 (mTORC1) coordinates cell growth and metabolism, acting as a restriction point under stress conditions such as low oxygen tension (hypoxia). Hypoxia suppresses mTORC1 signaling. However, the signals...
2.
Thimmaiah K, Easton J, Houghton P
Cancer Res
. 2010 Feb;
70(5):2000-9.
PMID: 20179209
Rapamycin-induced apoptosis in sarcoma cells is inhibited by insulin-like growth factor-I (IGF-I) through a signaling pathway independent of Ras-extracellular signal-regulated kinase 1/2 and Akt. IGF-I induces Bad phosphorylation (Ser112, Ser136,...
3.
Zhan J, Easton J, Huang S, Mishra A, Xiao L, Lacy E, et al.
Mol Cell Biol
. 2007 Feb;
27(9):3530-41.
PMID: 17325029
The cyclin-dependent kinase inhibitor p21(Cip1) regulates multiple cellular functions and protects cells from genotoxic and other cellular stresses. Activation of apoptosis signal-regulating kinase 1 (ASK1) induced by inhibition of mTOR...
4.
Easton J, Royer A, Middlemas D
J Neurochem
. 2006 Apr;
97(3):834-45.
PMID: 16573649
Brain-derived neurotrophic factor (BDNF) and other neurotrophins induce a unique prolonged activation of mitogen-activated protein kinase (MAPK) compared with growth factors. Characterization and kinetic and spatial modeling of the signaling...
5.
Easton J, Kurmasheva R, Houghton P
Cancer Cell
. 2006 Mar;
9(3):153-5.
PMID: 16530700
Rapamycin analogs that inhibit mTOR signaling have antitumor activity against certain lymphomas, but treatment of solid tumors has been less encouraging despite inhibition of mTOR function. Two recent papers give...
6.
Thimmaiah K, Easton J, Germain G, Morton C, Kamath S, Buolamwini J, et al.
J Biol Chem
. 2005 Jul;
280(36):31924-35.
PMID: 16009706
A series of 30 N10-substituted phenoxazines were synthesized and screened as potential inhibitors of Akt. In cellular assays at 5 mum, 17 compounds inhibited insulin-like growth factor 1 (IGF-I)-stimulated phosphorylation...
7.
Forino M, Jung D, Easton J, Houghton P, Pellecchia M
J Med Chem
. 2005 Apr;
48(7):2278-81.
PMID: 15801821
We examined some in silico approaches to identify Akt (protein kinase B) inhibitors. Experimental validation of selected compounds was achieved using a fluorescence-based enzymatic assay and a substrate phosphorylation assay...
8.
Easton J, Houghton P
Expert Opin Ther Targets
. 2004 Dec;
8(6):551-64.
PMID: 15584862
Target of rapamycin (TOR) functions within the cell as a transducer of information from various sources, including growth factors, energy sensors, and hypoxia sensors, as well as components of the...